

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

F1_R2

Date Report Reqsted: 08/09/2006

Time Report Reqsted: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

C Number: C97008

Lock Date: 08/16/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: 25021 TSAC

25020 NATD

25019 MSAC

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMS No. 97008 - 05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Date Report Requested: 08/09/2006

Test Type: CHRONIC

PROPARGYL ALCOHOL

Time Report Requested: 14:01:40

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 10/01/01 / 10/01/01

Species/Strain: RATS/F 344

Pathologist: HARBO, S. - LIEUALLEN, W.

Lab: BNW

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	20	19	26	30
Natural Death	2	8	9	4
Survivors				
Moribund Sacrifice	1			
Terminal Sacrifice	26	23	15	16
Animals Examined Microscopically	49	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(47)	(46)	(45)	(49)
Artery, Inflammation, Chronic Active	1 (2%)			
Intestine Large, Rectum	(47)	(47)	(46)	(50)
Edema	1 (2%)			
Inflammation, Suppurative	1 (2%)			
Intestine Small, Jejunum	(46)	(45)	(45)	(48)
Liver	(49)	(50)	(50)	(50)
Angiectasis	1 (2%)	3 (6%)		
Basophilic Focus	7 (14%)	18 (36%)	15 (30%)	4 (8%)
Clear Cell Focus	10 (20%)	13 (26%)	9 (18%)	4 (8%)
Degeneration, Cystic	3 (6%)	1 (2%)	1 (2%)	2 (4%)
Eosinophilic Focus	2 (4%)	4 (8%)	2 (4%)	5 (10%)
Hematopoietic Cell Proliferation	1 (2%)	1 (2%)	1 (2%)	
Hemorrhage			1 (2%)	
Hepatodiaphragmatic Nodule		5 (10%)	2 (4%)	1 (2%)
Inflammation, Granulomatous			1 (2%)	
Inflammation, Chronic Active	1 (2%)		1 (2%)	
Mixed Cell Focus	2 (4%)	4 (8%)	5 (10%)	3 (6%)
Necrosis	1 (2%)	2 (4%)	2 (4%)	2 (4%)
Vacuolization Cytoplasmic	7 (14%)	5 (10%)	3 (6%)	3 (6%)
Centrilobular, Degeneration	1 (2%)			1 (2%)
Hepatocyte, Regeneration				2 (4%)
Mesentery	(11)	(14)	(7)	(3)
Necrosis	10 (91%)	14 (100%)	7 (100%)	2 (67%)
Thrombosis				1 (33%)
Artery, Inflammation, Chronic Active	1 (9%)			

a - Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Oral Mucosa	(0)	(1)	(1)	(0)
Pancreas	(49)	(50)	(50)	(50)
Acinus, Atrophy	24 (49%)	21 (42%)	22 (44%)	26 (52%)
Acinus, Hyperplasia	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Duct, Necrosis			1 (2%)	
Salivary Glands	(49)	(50)	(50)	(50)
Stomach, Forestomach	(49)	(50)	(50)	(50)
Edema	1 (2%)			
Erosion		1 (2%)		1 (2%)
Hyperplasia, Squamous		3 (6%)	3 (6%)	
Inflammation, Chronic			1 (2%)	
Ulcer	4 (8%)	3 (6%)	3 (6%)	2 (4%)
Stomach, Glandular	(49)	(50)	(50)	(50)
Erosion	4 (8%)	2 (4%)	5 (10%)	3 (6%)
Ulcer	5 (10%)		1 (2%)	4 (8%)
Tongue	(1)	(0)	(2)	(1)
CARDIOVASCULAR SYSTEM				
Heart	(49)	(50)	(50)	(50)
Cardiomyopathy	44 (90%)	44 (88%)	44 (88%)	43 (86%)
Atrium, Thrombosis	3 (6%)	6 (12%)	8 (16%)	5 (10%)
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(50)	(50)
Degeneration, Cystic	1 (2%)			
Hematopoietic Cell Proliferation	1 (2%)			
Hyperplasia	19 (39%)	23 (46%)	27 (54%)	28 (56%)
Hypertrophy	1 (2%)			
Thrombosis			1 (2%)	
Vacuolization Cytoplasmic	11 (22%)	8 (16%)	9 (18%)	7 (14%)
Subcapsular, Hyperplasia	1 (2%)			
Adrenal Medulla	(49)	(50)	(50)	(50)
Hyperplasia	15 (31%)	19 (38%)	21 (42%)	18 (36%)
Infiltration Cellular, Lymphocyte	1 (2%)			
Islets, Pancreatic	(49)	(50)	(50)	(50)
Hyperplasia	1 (2%)	5 (10%)	1 (2%)	1 (2%)
Parathyroid Gland	(47)	(44)	(49)	(50)
Hyperplasia		2 (5%)		

TDMS No. 97008 - 05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Date Report Requested: 08/09/2006

Test Type: CHRONIC

PROPARGYL ALCOHOL

Time Report Requested: 14:01:40

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 10/01/01 / 10/01/01

Species/Strain: RATS/F 344

Pathologist: HARBO, S. - LIEUALLEN, W.

Lab: BNW

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Pituitary Gland	(49)	(50)	(50)	(50)
Hemorrhage		1 (2%)	3 (6%)	
Pars Distalis, Hyperplasia	8 (16%)	6 (12%)	6 (12%)	13 (26%)
Pars Intermedia, Cyst				1 (2%)
Thyroid Gland	(49)	(50)	(50)	(50)
Cyst		1 (2%)		
C-cell, Hyperplasia	8 (16%)	6 (12%)	15 (30%)	12 (24%)
Follicular Cell, Hyperplasia		1 (2%)		1 (2%)
GENERAL BODY SYSTEM				
Peritoneum	(1)	(0)	(0)	(0)
Tissue NOS	(1)	(0)	(0)	(0)
GENITAL SYSTEM				
Coagulating Gland	(0)	(0)	(1)	(0)
Inflammation, Suppurative			1 (100%)	
Epididymis	(49)	(50)	(50)	(50)
Penis	(0)	(0)	(0)	(1)
Inflammation, Suppurative				1 (100%)
Preputial Gland	(49)	(49)	(50)	(49)
Cyst			1 (2%)	
Hyperplasia				2 (4%)
Inflammation, Chronic Active	18 (37%)	12 (24%)	11 (22%)	12 (24%)
Necrosis				1 (2%)
Prostate	(49)	(50)	(50)	(50)
Hyperplasia	9 (18%)	2 (4%)	10 (20%)	8 (16%)
Inflammation, Suppurative	31 (63%)	41 (82%)	36 (72%)	34 (68%)
Inflammation, Chronic Active	4 (8%)		1 (2%)	2 (4%)
Seminal Vesicle	(49)	(50)	(50)	(50)
Hyperplasia	1 (2%)			
Testes	(49)	(50)	(50)	(50)
Germinal Epithelium, Atrophy	6 (12%)	3 (6%)	3 (6%)	4 (8%)
Interstitial Cell, Hyperplasia	4 (8%)	4 (8%)	7 (14%)	5 (10%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(50)
Myelofibrosis		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Requested: 08/09/2006

Time Report Requested: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Erythroid Cell, Hyperplasia		1 (2%)	2 (4%)	1 (2%)
Lymph Node	(5)	(3)	(7)	(8)
Deep Cervical, Hemorrhage	1 (20%)	1 (33%)	1 (14%)	
Deep Cervical, Hyperplasia, Lymphoid	1 (20%)			
Pancreatic, Angiectasis	2 (40%)			2 (25%)
Pancreatic, Infiltration Cellular, Histiocyte			1 (14%)	
Lymph Node, Bronchial	(6)	(4)	(8)	(7)
Angiectasis	1 (17%)		2 (25%)	
Hemorrhage			1 (13%)	
Hyperplasia, Lymphoid	1 (17%)	2 (50%)	1 (13%)	
Lymph Node, Mandibular	(0)	(1)	(1)	(0)
Hyperplasia, Lymphoid		1 (100%)		
Lymph Node, Mediastinal	(24)	(24)	(24)	(26)
Angiectasis		1 (4%)		
Hemorrhage		1 (4%)		
Hyperplasia, Lymphoid	3 (13%)	1 (4%)	3 (13%)	2 (8%)
Infiltration Cellular, Histiocyte	1 (4%)			
Inflammation, Chronic Active		1 (4%)		
Lymph Node, Mesenteric	(49)	(50)	(50)	(49)
Angiectasis	1 (2%)			
Ectasia	1 (2%)			
Hemorrhage	1 (2%)			
Hyperplasia, Lymphoid	1 (2%)		2 (4%)	
Infiltration Cellular, Histiocyte	9 (18%)	5 (10%)	5 (10%)	3 (6%)
Spleen	(49)	(50)	(49)	(49)
Angiectasis			1 (2%)	
Hematopoietic Cell Proliferation	8 (16%)	10 (20%)	5 (10%)	8 (16%)
Hemorrhage			1 (2%)	
Hemorrhage, Chronic	1 (2%)	3 (6%)	2 (4%)	
Hyperplasia, Lymphoid, Focal	1 (2%)			
Hyperplasia, Lymphoid			2 (4%)	
Infarct			1 (2%)	
Thymus	(47)	(43)	(46)	(45)
Cyst				1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(30)	(29)	(28)	(34)
Galactoceles		1 (3%)	1 (4%)	3 (9%)
Inflammation, Suppurative	1 (3%)			
Skin	(49)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Requested: 08/09/2006

Time Report Requested: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Cyst Epithelial Inclusion	2 (4%)		3 (6%)	
Ulcer	5 (10%)	1 (2%)	2 (4%)	1 (2%)
Subcutaneous Tissue, Fibrosis	1 (2%)			
Subcutaneous Tissue, Inflammation	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(49)	(50)	(50)	(50)
Hyperostosis		1 (2%)	1 (2%)	
NERVOUS SYSTEM				
Brain	(49)	(50)	(50)	(50)
Compression	10 (20%)	9 (18%)	18 (36%)	9 (18%)
Hemorrhage		1 (2%)	3 (6%)	2 (4%)
Necrosis	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Thrombosis				1 (2%)
RESPIRATORY SYSTEM				
Larynx	(48)	(50)	(50)	(50)
Foreign Body	2 (4%)	3 (6%)	1 (2%)	
Inflammation, Chronic Active	3 (6%)			
Metaplasia, Squamous	1 (2%)		1 (2%)	
Lung	(49)	(50)	(50)	(50)
Foreign Body	1 (2%)			
Hemorrhage		1 (2%)	3 (6%)	2 (4%)
Inflammation		1 (2%)		2 (4%)
Thrombosis			1 (2%)	1 (2%)
Alveolar Epithelium, Hyperplasia	8 (16%)	12 (24%)	11 (22%)	7 (14%)
Alveolar Epithelium, Metaplasia, Squamous	2 (4%)	1 (2%)		1 (2%)
Alveolus, Infiltration Cellular, Histiocyte	4 (8%)	1 (2%)		1 (2%)
Nose	(49)	(49)	(50)	(49)
Foreign Body	7 (14%)	8 (16%)	6 (12%)	8 (16%)
Hemorrhage				1 (2%)
Inflammation, Suppurative	1 (2%)	1 (2%)		
Inflammation, Chronic Active	9 (18%)	12 (24%)	22 (44%)	28 (57%)
Glands, Olfactory Epithelium, Hyperplasia				4 (8%)
Glands, Respiratory Epithelium, Hyperplasia	3 (6%)	14 (29%)	39 (78%)	45 (92%)
Olfactory Epithelium, Accumulation, Hyaline		5 (10%)	4 (8%)	7 (14%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Requested: 08/09/2006

Time Report Requested: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Droplet				
Olfactory Epithelium, Atrophy	1 (2%)	21 (43%)	26 (52%)	26 (53%)
Olfactory Epithelium, Degeneration			1 (2%)	7 (14%)
Olfactory Epithelium, Hyperplasia		1 (2%)	3 (6%)	5 (10%)
Olfactory Epithelium, Hyperplasia, Basal Cell		19 (39%)	42 (84%)	42 (86%)
Olfactory Epithelium, Metaplasia, Respiratory	1 (2%)	10 (20%)	18 (36%)	29 (59%)
Olfactory Epithelium, Necrosis			2 (4%)	6 (12%)
Respiratory Epithelium, Hyperplasia	5 (10%)	21 (43%)	44 (88%)	42 (86%)
Respiratory Epithelium, Metaplasia, Squamous	2 (4%)	2 (4%)	2 (4%)	4 (8%)
Pleura	(0)	(1)	(0)	(0)
SPECIAL SENSES SYSTEM				
Ear	(1)	(0)	(0)	(0)
Eye	(49)	(50)	(50)	(50)
Inflammation, Chronic Active			1 (2%)	
Cornea, Mineralization	1 (2%)			
Lens, Cataract	1 (2%)	3 (6%)	2 (4%)	
Zymbal's Gland	(0)	(1)	(0)	(0)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Cyst	1 (2%)	2 (4%)	3 (6%)	2 (4%)
Infarct	1 (2%)	1 (2%)	2 (4%)	
Inflammation, Suppurative	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Nephropathy, Chronic	42 (86%)	47 (94%)	48 (96%)	48 (96%)
Transitional Epithelium, Infarct			1 (2%)	
Urinary Bladder	(49)	(50)	(50)	(50)
Edema				1 (2%)
Inflammation, Chronic	1 (2%)		1 (2%)	
Transitional Epithelium, Hyperplasia	1 (2%)			

*** END OF MALE ***

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Requested: 08/09/2006

Time Report Requested: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	18	16	19	19
Natural Death	3	3	4	5
Survivors				
Natural Death		1		
Terminal Sacrifice	29	30	27	26
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(48)	(48)	(47)	(46)
Ulcer		1 (2%)		
Serosa, Inflammation	1 (2%)			
Intestine Large, Colon	(48)	(48)	(47)	(47)
Serosa, Inflammation	1 (2%)			
Intestine Small, Duodenum	(49)	(50)	(48)	(47)
Serosa, Inflammation	1 (2%)			
Intestine Small, Ileum	(48)	(48)	(46)	(46)
Intestine Small, Jejunum	(48)	(48)	(47)	(46)
Liver	(50)	(50)	(50)	(50)
Angiectasis		4 (8%)	1 (2%)	1 (2%)
Basophilic Focus	37 (74%)	36 (72%)	40 (80%)	31 (62%)
Clear Cell Focus	6 (12%)	6 (12%)	7 (14%)	7 (14%)
Eosinophilic Focus		2 (4%)	3 (6%)	3 (6%)
Fibrosis	1 (2%)			
Hepatodiaphragmatic Nodule	3 (6%)	2 (4%)	5 (10%)	2 (4%)
Inflammation, Granulomatous	1 (2%)			
Inflammation, Chronic Active	1 (2%)		2 (4%)	1 (2%)
Mixed Cell Focus	5 (10%)	4 (8%)	4 (8%)	12 (24%)
Necrosis		1 (2%)		2 (4%)
Vacuolization Cytoplasmic	8 (16%)	3 (6%)	3 (6%)	4 (8%)
Centrilobular, Necrosis	1 (2%)			1 (2%)
Oval Cell, Hyperplasia				1 (2%)
Mesentery	(13)	(12)	(10)	(9)
Necrosis	13 (100%)	12 (100%)	10 (100%)	9 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Oral Mucosa	(1)	(0)	(2)	(1)
Foreign Body	1 (100%)		1 (50%)	
Ulcer			1 (50%)	
Pancreas	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Acinus, Atrophy	6 (12%)	9 (18%)	11 (22%)	14 (28%)
Acinus, Inflammation, Chronic				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Necrosis				1 (2%)
Ulcer	3 (6%)	5 (10%)	1 (2%)	2 (4%)
Epithelium, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
Serosa, Inflammation	1 (2%)			
Stomach, Glandular	(49)	(50)	(50)	(48)
Erosion	3 (6%)	1 (2%)	1 (2%)	3 (6%)
Ulcer	1 (2%)		1 (2%)	1 (2%)
Serosa, Inflammation	1 (2%)			
Tongue	(0)	(0)	(2)	(1)
Inflammation, Granulomatous, Chronic				1 (100%)
Active				
Epithelium, Hyperplasia			1 (50%)	
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	43 (86%)	45 (90%)	42 (84%)	42 (84%)
Atrium, Thrombosis	2 (4%)		2 (4%)	4 (8%)
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis	3 (6%)			
Degeneration, Cystic			1 (2%)	2 (4%)
Hemorrhage				1 (2%)
Hyperplasia	28 (56%)	23 (46%)	22 (44%)	21 (42%)
Necrosis	1 (2%)	1 (2%)		
Vacuolization Cytoplasmic	3 (6%)	3 (6%)	1 (2%)	4 (8%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	5 (10%)	7 (14%)	3 (6%)	2 (4%)
Necrosis	1 (2%)			

TDMS No. 97008 - 05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Date Report Requested: 08/09/2006

Test Type: CHRONIC

PROPARGYL ALCOHOL

Time Report Requested: 14:01:40

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 10/01/01 / 10/01/01

Species/Strain: RATS/F 344

Pathologist: HARBO, S. - LIEUALLEN, W.

Lab: BNW

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	4 (8%)	4 (8%)	
Parathyroid Gland	(49)	(47)	(50)	(47)
Pituitary Gland	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)	5 (10%)	2 (4%)	3 (6%)
Pars Distalis, Cyst	4 (8%)	2 (4%)	3 (6%)	
Pars Distalis, Hyperplasia	11 (22%)	5 (10%)	6 (12%)	9 (18%)
Thyroid Gland	(50)	(50)	(50)	(50)
C-cell, Hyperplasia	21 (42%)	16 (32%)	18 (36%)	18 (36%)
GENERAL BODY SYSTEM				
Tissue NOS	(1)	(0)	(1)	(0)
Fat, Inflammation, Chronic	1 (100%)			
GENITAL SYSTEM				
Clitoral Gland	(50)	(49)	(49)	(47)
Cyst	1 (2%)		1 (2%)	
Hyperplasia	4 (8%)	4 (8%)	4 (8%)	5 (11%)
Inflammation, Suppurative			1 (2%)	1 (2%)
Inflammation, Chronic Active	8 (16%)	4 (8%)	9 (18%)	5 (11%)
Ovary	(50)	(50)	(50)	(50)
Cyst	6 (12%)	5 (10%)	6 (12%)	8 (16%)
Inflammation	1 (2%)			
Interstitial Cell, Hyperplasia	5 (10%)	8 (16%)	3 (6%)	6 (12%)
Uterus	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Cyst			1 (2%)	
Decidual Reaction			1 (2%)	
Dilatation			1 (2%)	
Fibrosis	1 (2%)	1 (2%)		1 (2%)
Hemorrhage	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Inflammation, Chronic Active				1 (2%)
Endometrium, Hyperplasia, Cystic	3 (6%)	3 (6%)	8 (16%)	5 (10%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Erythroid Cell, Hyperplasia	1 (2%)	3 (6%)	4 (8%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 97008 - 05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Date Report Requested: 08/09/2006

Test Type: CHRONIC

PROPARGYL ALCOHOL

Time Report Requested: 14:01:40

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 10/01/01 / 10/01/01

Species/Strain: RATS/F 344

Pathologist: HARBO, S. - LIEUALLEN, W.

Lab: BNW

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Lymph Node	(4)	(0)	(3)	(3)
Deep Cervical, Angiectasis				1 (33%)
Pancreatic, Angiectasis			1 (33%)	
Lymph Node, Bronchial	(4)	(2)	(4)	(10)
Angiectasis			1 (25%)	1 (10%)
Hyperplasia, Lymphoid				2 (20%)
Lymph Node, Mediastinal	(29)	(27)	(30)	(25)
Angiectasis			1 (3%)	
Hyperplasia, Lymphoid			1 (3%)	
Infiltration Cellular, Histiocyte	1 (3%)	1 (4%)		
Lymph Node, Mesenteric	(49)	(50)	(49)	(50)
Angiectasis	1 (2%)	1 (2%)		1 (2%)
Hemorrhage		1 (2%)		
Hyperplasia, Lymphoid	2 (4%)			
Infiltration Cellular, Histiocyte	9 (18%)	9 (18%)	3 (6%)	4 (8%)
Spleen	(50)	(50)	(50)	(49)
Accessory Spleen	1 (2%)			
Hematopoietic Cell Proliferation	21 (42%)	26 (52%)	22 (44%)	17 (35%)
Hemorrhage, Chronic	1 (2%)			1 (2%)
Capsule, Fibrosis		1 (2%)		1 (2%)
Thymus	(46)	(45)	(47)	(48)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Galactoceles	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Hyperplasia	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Epithelium, Hyperplasia			1 (2%)	1 (2%)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1 (2%)			1 (2%)
Inflammation, Granulomatous				1 (2%)
Ulcer	1 (2%)	1 (2%)	1 (2%)	
Subcutaneous Tissue, Hemorrhage				1 (2%)
Subcutaneous Tissue, Inflammation	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Hyperostosis		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Requested: 08/09/2006

Time Report Requested: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Nasal, Inflammation, Chronic Active				1 (2%)
Skeletal Muscle	(2)	(0)	(1)	(0)
Fat, Necrosis	1 (50%)			
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Compression	6 (12%)	11 (22%)	4 (8%)	9 (18%)
Hemorrhage	2 (4%)			2 (4%)
Inflammation, Suppurative				1 (2%)
Inflammation, Chronic Active	1 (2%)			
Necrosis				1 (2%)
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Foreign Body	2 (4%)	3 (6%)	2 (4%)	6 (12%)
Inflammation, Chronic Active		1 (2%)		3 (6%)
Metaplasia, Squamous	1 (2%)			2 (4%)
Lung	(50)	(50)	(50)	(50)
Foreign Body				1 (2%)
Hemorrhage			1 (2%)	
Inflammation	1 (2%)			
Inflammation, Suppurative				1 (2%)
Alveolar Epithelium, Hyperplasia	7 (14%)	12 (24%)	13 (26%)	5 (10%)
Alveolar Epithelium, Metaplasia, Squamous			1 (2%)	
Alveolus, Infiltration Cellular, Histiocyte	3 (6%)	3 (6%)	1 (2%)	2 (4%)
Nose	(49)	(49)	(50)	(50)
Foreign Body	1 (2%)	4 (8%)	4 (8%)	6 (12%)
Inflammation, Suppurative			1 (2%)	
Inflammation, Chronic Active	7 (14%)	9 (18%)	11 (22%)	18 (36%)
Epithelium, Nasolacrimal Duct, Hyperplasia	1 (2%)			
Glands, Olfactory Epithelium, Hyperplasia		6 (12%)	1 (2%)	2 (4%)
Glands, Respiratory Epithelium, Hyperplasia	2 (4%)	33 (67%)	44 (88%)	47 (94%)
Nasolacrimal Duct, Inflammation, Chronic Active	3 (6%)	1 (2%)		
Olfactory Epithelium, Accumulation, Hyaline Droplet	6 (12%)	5 (10%)	6 (12%)	15 (30%)
Olfactory Epithelium, Atrophy	3 (6%)		28 (56%)	37 (74%)
Olfactory Epithelium, Degeneration			1 (2%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 97008 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Requested: 08/09/2006

Time Report Requested: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Olfactory Epithelium, Hyperplasia				1 (2%)
Olfactory Epithelium, Hyperplasia, Basal Cell		28 (57%)	42 (84%)	48 (96%)
Olfactory Epithelium, Metaplasia, Respiratory	3 (6%)	2 (4%)	7 (14%)	17 (34%)
Olfactory Epithelium, Metaplasia, Squamous				1 (2%)
Olfactory Epithelium, Necrosis			2 (4%)	5 (10%)
Respiratory Epithelium, Hyperplasia	2 (4%)	23 (47%)	25 (50%)	36 (72%)
Respiratory Epithelium, Metaplasia, Squamous		1 (2%)		4 (8%)
SPECIAL SENSES SYSTEM				
Eye	(49)	(50)	(50)	(50)
Inflammation, Suppurative	1 (2%)			
Lens, Cataract	4 (8%)	5 (10%)	8 (16%)	3 (6%)
Zymbal's Gland	(0)	(0)	(2)	(1)
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(49)
Infarct	1 (2%)	1 (2%)		1 (2%)
Inflammation, Suppurative				1 (2%)
Nephropathy, Chronic	40 (80%)	46 (92%)	41 (82%)	44 (90%)
Bilateral, Hydronephrosis			1 (2%)	
Pelvis, Transitional Epithelium, Hyperplasia			1 (2%)	
Urinary Bladder	(49)	(50)	(50)	(49)

*** END OF REPORT ***